International Society for Cellular Therapy

Nonprofit profile at a glance

EIN
521809771
IRS 990 coverage
2014–2024
Forms available
Form 990 2024
Location
Vancouver, British Columbia, CA
Phone
6048744366
Rating
69
Verdict
SUPPORTED
Rating confidence
Moderate

Official website

Reported finances

Revenue
$7,494,736
Expenses
$4,122,550
Assets
$13,218,140
Liabilities
$2,211,865

Source: IRS Form 990. Selected filing: tax year 2024. Amounts in USD.

Leadership & pay

41 people listed

Executive titles in this filing

  • QUEENIE JANG (CHIEF EXECUTIVE OFFICER)
  • DANIEL WEISS (PRESIDENT-ELECT)
  • MIGUEL FORTE (PRESIDENT)
  • BRUCE LEVINE (PREVIOUS PRESIDENT TO JUNE 2024)

Highest reported compensation

  • QUEENIE JANG (CHIEF EXECUTIVE OFFICER): $305,828 total reported compensation
  • AUDREY LE (VP, GLOBAL OPERATIONS): $121,964 total reported compensation
  • RAYMOND LAM (ASSOCIATE DIRECTOR): $111,197 total reported compensation

Source: IRS Form 990. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

See schedule o.the mission of international society of cellular therapy (isct) is to drive clinical translation of cell and gene therapies worldwide. Isct is a global society of clinicians, regulators, technologists, and industry partners working to translate cellular therapy into safe and effective therapies to improve patients' lives.

What it reported doing in 2024

Cytotherapy, the official journal of isct, publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. In addition to short reports and full-length articles, the journal also accepts editorials on emerging trends and potential controversies in the field and review articles summarizing important areas of cell and gene therapy research that are topical and/or challenge existing paradigms in the field.cytotherapy considers manuscripts exploring the following topics:- gene, cell (includes stem cells and ipscs) and evidence-based therapies- regulatory frameworks and policy issues in cgt (cell and gene therapy)- novel and innovative results from basic, translational, and clinical studies in cgt- important advances in cell/gene-based product manufacturing, commercialization, and patient access - clinical studies evaluating the safety and efficacy of cell and gene therapiescytotherapy does not publish manuscripts on the following topics:- case studies unless they are of unusual significance to the field- basic/translational studies exploring the role of lncrnas, circrnas, and mirnas in disease pathophysiology- studies describing signaling pathways implicated in cancer

Operating model

Revenue model
Earned-program. 92% of the money available for current operations came from fees and other program revenue.
Distribution model
Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.

The verdict

SUPPORTED - The filed numbers largely add up and most voting board members are independent. A relatively small share of available resources goes toward mission work and the filing reports few safeguards for money sent abroad.

Rating breakdown

  • Financial Efficiency: 53
  • Transparency & Controls: 74
  • Accountability: 86
  • Sustainability: 73
  • Growth: 100

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 44.4%; rating input score 44
  • Program expense ratio: 87.2%; rating input score 87
  • Fundraising efficiency: Limited

Transparency & Controls

  • Consistency checks: 93.3%; rating input score 93; 17th percentile among comparable filings
  • Pay-setting controls: 5 of 6 controls in place; rating input score 83
    • Compensation committee: Pass
    • Independent consultant: Missing
    • Other Form 990s reviewed: Pass
    • Written employment contract: Pass
    • Compensation survey or study: Pass
    • Board or committee approval: Pass
  • Foreign activity oversight: 1 of 8 controls in place; rating input score 12
    • Claims monitoring procedures: Pass
    • Requires narrative reports: Fail
    • Conducts field audits: Fail
    • May suspend future funding: Fail
    • Requires financial reports: Fail
    • Conducts site visits: Fail
    • Requires grant agreements: Fail
    • May require repayment: Fail
  • Grant itemization coverage: 100%; rating input score 100; 72nd percentile among comparable filings
  • Major donor itemization: Limited
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 83.3%; rating input score 83; 16th percentile among comparable filings
  • Governance controls: 8 of 9 controls in place; rating input score 89
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Pass
    • Document-retention policy: Pass
    • CEO compensation review process: Pass
    • Other executive compensation review process: Fail
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Pass
    • Independent financial-statement audit: Pass

Sustainability

  • Operating margin: 45%; rating input score 91; 91st percentile among comparable filings
  • Total-asset coverage ratio: 3.21; rating input score 75; 75th percentile among comparable filings
  • Liabilities to assets ratio: 0.17; rating input score 48; 48th percentile among comparable filings
  • Officer compensation ratio: 14%; rating input score 20; 20th percentile among comparable filings

Growth

  • Program expense growth: 7.9% per year; rating input score 100; 55th percentile among comparable filings
  • Revenue growth: 12.9% per year; rating input score 100; 77th percentile among comparable filings
  • Asset growth: 21.3% per year; rating input score 100; 86th percentile among comparable filings

Details

  • Where the money goes: 44.4% of revenue deployed · 87.2% of spending went to programs
  • Governance: 15 of 18 board members independent · 8 of 9 filing controls reported
  • Programs: 4 filed program accomplishments · $3.6M in reported program spending
  • Leadership: top reported pay $306K · 41 people listed · 5 of 6 pay-setting controls reported
  • Consistency: 36 of 36 current checks pass
  • Schedules: 6 filed schedules · includes foreign activity, grants, and executive pay
  • Filing history: 10 filing years from 2014 to 2024
  • Contacts: How to reach this organization
  • Money network: 6 filed money-flow records
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • Moderate — Financial Efficiency: Mission deployment rate scored 44/100.
  • High — Transparency & Controls: Foreign activity oversight: 7 of 8 not reported.
  • Review — Accountability: Governance controls: Other executive compensation review process not reported.
  • High — Sustainability: Officer compensation ratio scored 20/100.
  • Moderate — Sustainability: Liabilities to assets ratio scored 48/100.